Our Mission and Impact
Addressing critical unmet needs in Patient-Focused Drug Development (PFDD) by incorporating the voice of patients, drug developers in industry and academia, and regulatory agencies
Focus on Model-Informed Drug Development (MIDD) through generation of novel, regulatory-endorsed quantitative drug development tools (DDTs) and solutions
Therapeutic innovation, optimization of trial design, development of novel analytical and statistical methodologies aimed at meaningful therapies in Alzheimer’s disease
– Michael C. Irizarry
SVP, Clinical Research, Neurology Business Group,
Eisai, and CPAD Industry Co-Director
Who we are
The Critical Path for Alzheimer’s Disease (CPAD) consortium is a pre-competitive public-private partnership (PPP) dedicated to enhancing regulatory decision-making tools to accelerate and de-risk drug development for Alzheimer’s disease and related dementia (ADRD).
Why we do it
Advantages of CPAD Consortium
How we do it
- CPAD is a global, neutral convener, bringing together diverse stakeholders across industry, regulatory agencies, and academia within a pre-competitive forum under a data-driven, regulatory framework to accelerate therapeutic innovation in AD.
- Leveraging the intellectual talent within CPAD and wealth of scientific knowledge gained from patient-level data contributions to CPAD, we identify the most critical unmet needs in AD and use our core competencies on data management, aggregation and analysis for informed decision making in AD drug development.
